Clinical Trials Browser

Phase 2 × Glioma × Aprepitant × Clear all

NCT01450826 2018-06-26

Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide

Phase 2 Completed

136 enrolled 10 charts

Glioma, Nausea, Vomiting